Ruxolitinib in refractory acute and chronic graft-versus-host disease : a multicenter survey study
Escamilla Gómez, Virginia (Universidad de Sevilla)
García-Gutiérrez, Valentín (University Hospital Ramon y Cajal)
López Corral, Lucía (Complejo Asistencial Universitario de Salamanca-IBSAL)
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau)
Pérez Martínez, Ariadna (Hospital Clínic Universitari (València))
Márquez Malaver, Francisco J. (Universidad de Sevilla)
Caballero Velazquez, Teresa (Universidad de Sevilla)
González Sierra, Pedro A. (Hospital Universitario (Granada))
Viguria Alegría, María C. (Complejo Hospitalario de Navarra)
Parra Salinas, Ingrid M. (Hospital Universitario Miguel Servet (Saragossa))
Calderón Cabrera, Cristina (Universidad de Sevilla)
González Vicent, Marta (Hospital Infantil Universitario Niño Jesús (Madrid))
Rodríguez Torres, Nancy (Universidad de Sevilla)
Parody Porras, Rocío (Instituto Catalá de Oncología Hospitalet)
Ferrá, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Orti, Guillermo (Hospital Universitari Vall d'Hebron)
Valcárcel Ferreiras, David (Hospital Universitari Vall d'Hebron)
de la Camara, Rafael (Hospital Universitario de la Princesa (Madrid))
Molés, Paula (Hospital Universitari i Politècnic La Fe (València))
Velázquez-Kennedy, Kyra (Hospital Universitario Ramón y Cajal (Madrid))
João Mende, María (Complejo Asistencial Universitario de Salamanca-IBSAL)
Caballero Barrigón, Dolores (Complejo Asistencial Universitario de Salamanca-IBSAL)
Pérez, Estefanía (Complejo Asistencial Universitario de Salamanca-IBSAL)
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau)
Saavedra Gerosa, Silvanna (Institut d'Investigació Biomèdica Sant Pau)
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau)
Poch, Marc (Clinic Hospital Universitari de Valencia)
Zudaire Ripa, María T. (Complejo Hospitalario de Navarra)
Díaz Pérez, Miguel A. (Hospital Infantil Universitario Niño Jesús (Madrid))
Molina Angulo, Blanca (Hospital Infantil Universitario Niño Jesús (Madrid))
Sánchez Ortega, Isabel (Instituto Catalá de Oncología Hospitalet)
Sanz Caballer, Jaime (Hospital Universitari i Politècnic La Fe (València))
Montoro Gómez, Juan (Hospital Universitari i Politècnic La Fe (València))
Espigado Tocino, Ildefonso (Universidad de Sevilla)
Pérez-Simón, José A. (Universidad de Sevilla)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69. 5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21. 7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57. 1% (32/56) with 3. 5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57. 1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69. 5% and 57. 1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
Grants:	Ministerio de Economía y Competitividad CB16/12/00480
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Drug development ; Molecularly targeted therapy
Published in:	Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 641-648, ISSN 1476-5365

DOI: 10.1038/s41409-019-0731-x
PMID: 31700138

8 p, 930.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles